CureDuchenne makes second investment in Tevard Bio’s work on DMD suppressor tRNA therapy

CureDuchenne, the Newport Beach, California-based nonprofit venture philanthropy organization, has announced a second investment in Tevard Biosciences to support development of the company’s suppressor tRNA therapy platform for Duchenne muscular dystrophy driven by nonsense mutations. The follow-on investment continues a relationship that began in 2023 and comes as Tevard prepares to present preclinical data publicly for the first time at the CureDuchenne FUTURES National Conference on May 22, 2026.

Financial terms were not disclosed. CureDuchenne confirmed the transaction as a second investment, with the first having been made in 2023, but no investment amount, equity stake, instrument type, or total committed capital was provided for either tranche. CureDuchenne’s broader portfolio has deployed more than USD 27 million across 19 programs that have advanced to human clinical trials. The deal is structured as venture philanthropy rather than a traditional licensing or co-development agreement.

Asset profile and platform status

Tevard’s suppressor tRNA therapy platform targets the subset of Duchenne muscular dystrophy patients whose disease is caused by nonsense mutations, which account for approximately 12% of the total DMD population. Nonsense mutations introduce a premature stop codon into the dystrophin gene, halting translation before a full-length protein can be assembled. Tevard’s approach uses engineered suppressor tRNA molecules to read through those premature stop codons, enabling the cell’s existing translational machinery to produce full-length, natural dystrophin protein rather than a truncated or absent form.

The platform remains in preclinical development, with no disclosed drug candidates at present. The company’s latest-generation suppressor tRNA candidates have generated preclinical data showing restoration of an average of 70% of wild-type dystrophin protein levels in DMD disease models, alongside functional improvements and durable protein expression following a single intravenous dose.

Suppressor tRNA therapy Duchenne: preclinical data and unmet need

No approved therapies exist specifically for the nonsense mutation class of Duchenne muscular dystrophy, leaving a defined patient subset with limited treatment options. Tevard’s preclinical readout — 70% wild-type dystrophin restoration with durable expression after a single IV dose — represents the most detailed public data the company has released for its latest-generation candidates, and the May 22 FUTURES conference presentation will mark the first time that data has been shared directly with the Duchenne patient and advocacy community. CureDuchenne will also host a webinar with Tevard on May 28, 2026, open to families, clinicians, researchers, and advocates.

The mutation-specific, nonsense-readthrough mechanism differentiates Tevard’s approach from exon-skipping strategies, which address different mutation classes and produce internally truncated rather than full-length dystrophin. The 70% restoration figure, if reproduced in clinical settings, would exceed the protein expression thresholds associated with some existing DMD modalities, though the preclinical-to-clinical translation of dystrophin restoration data has historically been variable across DMD gene therapy and molecular programs.

Suppressor tRNA therapy Duchenne: deal context and prior transactions

CureDuchenne has established a pattern of early-stage equity investment in DMD platform companies across multiple modalities. In May 2023, CureDuchenne Ventures invested in MyoGene Bio to advance an AAV-delivered CRISPR/Cas9 gene editing therapy targeting exon 45–55 deletions in DMD. In May 2025, the organization made an initial USD 1 million investment in Entos Pharmaceuticals to support development of a redosable, non-viral, full-length dystrophin gene therapy. The Tevard follow-on investment places the company alongside those programs as a recurring CureDuchenne portfolio holding rather than a one-time grant recipient.

Tevard itself has prior institutional validation for its tRNA platform in DMD. In February 2023, the company entered a four-year global research collaboration and option-to-license agreement with Vertex Pharmaceuticals to develop tRNA-based therapies for nonsense-mutation DMD, with options to expand into additional muscular dystrophies. That transaction established a major pharma co-development relationship for the same platform now receiving continued CureDuchenne support. The CureDuchenne Tevard partnership therefore operates alongside, rather than in place of, the Vertex collaboration, suggesting Tevard is advancing the platform through multiple funding channels simultaneously.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/